D Tomek

PCV57 COSTS OF ATRIAL FIBRILLATION IN SLOVAKIA FROM A PAYER PERSPECTIVE

the care pathway to ensure rapid assessment and treatment for TIA patients would avoid 128 future stroke events over three years. As a result, the costs associated with the reconfiguration of the TIA patient care pathway would be partially offset by savings in acute stroke management costs. CONCLUSIONS: Our model suggests that implementing a revised TIA care pathway in Hungary would result in a reduction of TIA-related recurrent strokes, leading to reduced costs associated with the acute management of stroke. This would partially offset the costs of establishing rapid assessment and treatment clinics for patients experiencing TIA.

PCV8 COST OF ILLNESS IN PATIENTS WITH PULMONARY EMBOLISM AFTER ELECTIVE TOTAL HIP REPLACEMENT

economic evaluations studies published to date regarding these three drugs. METHODS: The economic impact was determined comparing the annual costs with drug and adjuvant therapy. The prices established by government for these drugs in renal transplantation were considered. Leaflet’s recommendations were followed for everolimus and MMF dosages. The dosage of azathioprine was based on clinical trials. The average cyclosporine dosages were taken according to the respective treatment available in clinical trials. Cochrane, Pubmed and Medline databases were used for pharmacoeconomic studies research. RESULTS: The most cost-saving therapy was found to be azathioprine, followed by everolimus, with the incremental annual cost of US

title

2862.81 (R

Patient Reported Outcomes with Multiple Sclerosis in Slovakia

2.27/USD 1.00) compared to azathioprine. The third is MMF, showing US

Quality of Life in Patients with Multiple Sclerosis in Slovakia

704.69 of incremental cost compared to everolimus. According to the reviewed economic studies, everolimus is the most effective for the prevention/ stabilization of CAV (cardiac allograft vasculopathy) and is associated with economic benefits due to its association with reduced hospitalization days due to Major Acute Cardiac Events (MACE). Both everolimus and MMF are more cost-effective than azathioprine in the first 6 months after heart transplantation, with everolimus presenting a more favorable ratio than MMF. CONCLUSIONS: Azathioprine is the cheapest drug for prophylaxis of cardiac transplant rejection. However there are important economic studies assessing the cost benefit of treatment outcome that have to be considered. One of the most important aspect is the effectiveness of preventing CAV, the major cause of late morbity and mortality following heart transplantation. To date, re-transplantation remains the only definite treatment for severe CAV, but there are ethical, cost concerns and poorer outcomes compared to primary transplantation that appear to be hurdles to re-transplantation.